205 related articles for article (PubMed ID: 18159033)
21. Natalizumab-associated cerebellar PML: a case report on how to slow down IRIS.
Lauda F; Fangerau T; Javaheripour-Otto K; Pinkhardt E; Kassubek J; Tumani H
J Neurol; 2015; 262(4):1055-7. PubMed ID: 25663412
[No Abstract] [Full Text] [Related]
22. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project.
Carson KR; Focosi D; Major EO; Petrini M; Richey EA; West DP; Bennett CL
Lancet Oncol; 2009 Aug; 10(8):816-24. PubMed ID: 19647202
[TBL] [Abstract][Full Text] [Related]
23. Monoclonal antibodies in treatment of multiple sclerosis.
Rommer PS; Dudesek A; Stüve O; Zettl UK
Clin Exp Immunol; 2014 Mar; 175(3):373-84. PubMed ID: 24001305
[TBL] [Abstract][Full Text] [Related]
24. Lessons for clinical trials from natalizumab in multiple sclerosis.
Chaudhuri A
BMJ; 2006 Feb; 332(7538):416-9. PubMed ID: 16484271
[TBL] [Abstract][Full Text] [Related]
25. Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis.
Dorsey ER; Thompson JP; Noyes K; Dick AW; Holloway RG; Schwid SR
Neurology; 2007 May; 68(18):1524-8. PubMed ID: 17470756
[TBL] [Abstract][Full Text] [Related]
26. Switching patients at high risk of PML from natalizumab to another disease-modifying therapy.
Giovannoni G; Marta M; Davis A; Turner B; Gnanapavan S; Schmierer K
Pract Neurol; 2016 Oct; 16(5):389-93. PubMed ID: 27114560
[TBL] [Abstract][Full Text] [Related]
27. Natalizumab: bound to rebound?
Schiess N; Calabresi PA
Neurology; 2009 Feb; 72(5):392-3. PubMed ID: 19188569
[No Abstract] [Full Text] [Related]
28. Hydrocephalus during natalizumab treatment.
Zecca C; Städler C; Gobbi C
Neurol Sci; 2010 Oct; 31(5):635-7. PubMed ID: 20454819
[TBL] [Abstract][Full Text] [Related]
29. [Natalizumab in multiple sclerosis: unclear patient benefits].
Schipper JP
Ned Tijdschr Geneeskd; 2007 Apr; 151(15):852-5. PubMed ID: 17472115
[TBL] [Abstract][Full Text] [Related]
30. Tysabri's return draws cautious optimism. Pharmacies, infusion centers must register to participate.
Traynor K
Am J Health Syst Pharm; 2006 Aug; 63(15):1388, 1392. PubMed ID: 16849700
[No Abstract] [Full Text] [Related]
31. Deaths and disability from natalizumab are no longer tolerable: Commentary.
Hutchinson M
Mult Scler; 2012 Aug; 18(8):1073. PubMed ID: 22807472
[No Abstract] [Full Text] [Related]
32. Transient punctuate enhancing lesions preceding natalizumab-associated progressive multifocal leukoencephalopathy.
Taieb G; Renard D; Thouvenot E; Servillo G; Castelnovo G
J Neurol Sci; 2014 Nov; 346(1-2):364-5. PubMed ID: 25241939
[No Abstract] [Full Text] [Related]
33. PML risk and natalizumab: more questions than answers.
Ransohoff RM
Lancet Neurol; 2010 Mar; 9(3):231-3. PubMed ID: 20117056
[No Abstract] [Full Text] [Related]
34. Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.
Peaureaux D; Pignolet B; Biotti D; Bucciarelli F; Gaina J; Bucur C; Clanet M; Martin-Blondel G; Brassat D
Mult Scler; 2015 Apr; 21(5):671-2. PubMed ID: 25305251
[No Abstract] [Full Text] [Related]
35. Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango.
Gupta S; Weinstock-Guttman B
Expert Opin Biol Ther; 2014 Jan; 14(1):115-26. PubMed ID: 24289270
[TBL] [Abstract][Full Text] [Related]
36. [Natalizumab can induce progressive multifocal leucoencephalopathy].
Theódórsdóttir A; Blaabjerg M; Falah M
Ugeskr Laeger; 2014 Aug; 176(35):. PubMed ID: 25293706
[TBL] [Abstract][Full Text] [Related]
37. Natalizumab.
Berger JR
Drugs Today (Barc); 2006 Oct; 42(10):639-55. PubMed ID: 17136224
[TBL] [Abstract][Full Text] [Related]
38. Safety of monoclonal antibodies for the treatment of multiple sclerosis.
McGinley MP; Moss BP; Cohen JA
Expert Opin Drug Saf; 2017 Jan; 16(1):89-100. PubMed ID: 27756172
[TBL] [Abstract][Full Text] [Related]
39. Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab.
Calic Z; Cappelen-Smith C; Hodgkinson SJ; McDougall A; Cuganesan R; Brew BJ
J Clin Neurosci; 2015 Mar; 22(3):598-600. PubMed ID: 25523125
[TBL] [Abstract][Full Text] [Related]
40. PML in natalizumab-treated multiple sclerosis: Modeling errors and risk miscalculations.
Mowry EM; McArthur JC
Neurology; 2017 Mar; 88(12):1110-1111. PubMed ID: 28228562
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
